Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jul 4;25(13):7347.
doi: 10.3390/ijms25137347.

Exploring Molecular Mechanisms and Biomarkers in COPD: An Overview of Current Advancements and Perspectives

Affiliations
Review

Exploring Molecular Mechanisms and Biomarkers in COPD: An Overview of Current Advancements and Perspectives

Chin-Ling Li et al. Int J Mol Sci. .

Abstract

Chronic obstructive pulmonary disease (COPD) plays a significant role in global morbidity and mortality rates, typified by progressive airflow restriction and lingering respiratory symptoms. Recent explorations in molecular biology have illuminated the complex mechanisms underpinning COPD pathogenesis, providing critical insights into disease progression, exacerbations, and potential therapeutic interventions. This review delivers a thorough examination of the latest progress in molecular research related to COPD, involving fundamental molecular pathways, biomarkers, therapeutic targets, and cutting-edge technologies. Key areas of focus include the roles of inflammation, oxidative stress, and protease-antiprotease imbalances, alongside genetic and epigenetic factors contributing to COPD susceptibility and heterogeneity. Additionally, advancements in omics technologies-such as genomics, transcriptomics, proteomics, and metabolomics-offer new avenues for comprehensive molecular profiling, aiding in the discovery of novel biomarkers and therapeutic targets. Comprehending the molecular foundation of COPD carries substantial potential for the creation of tailored treatment strategies and the enhancement of patient outcomes. By integrating molecular insights into clinical practice, there is a promising pathway towards personalized medicine approaches that can improve the diagnosis, treatment, and overall management of COPD, ultimately reducing its global burden.

Keywords: chronic obstructive pulmonary disease; epigenetics and gene regulation; molecular biomarkers; molecular pathogenesis; precision medicine; targeted therapies.

PubMed Disclaimer

Conflict of interest statement

The author declares no conflicts of interest.

Figures

Figure 1
Figure 1
The flow of factors contributing to COPD pathogenesis.

References

    1. Kim J., Lee J.H., Kim Y., Kim K., Oh Y.M., Yoo K.H., Rhee C.K., Yoon H.K., Kim Y.S., Park Y.B., et al. Association between chronic obstructive pulmonary disease and gastroesophageal reflux disease: A national cross-sectional cohort study. BMC Pulm. Med. 2013;13:51. doi: 10.1186/1471-2466-13-51. - DOI - PMC - PubMed
    1. López-Campos J.L., Tan W., Soriano J.B. Global burden of COPD. Respirology. 2016;21:14–23. doi: 10.1111/resp.12660. - DOI - PubMed
    1. Shaddock E., Richards G. Pharmacological management of chronic obstructive pulmonary disease. S. Afr. Med. J. 2015;105:790. doi: 10.7196/SAMJnew.8426. - DOI - PubMed
    1. Iheanacho I., Zhang S., King D., Rizzo M., Ismaila A.S. Economic burden of chronic obstructive pulmonary disease (COPD): A systematic literature review. Int. J. Chronic Obstr. Pulm. Dis. 2020;15:439–460. doi: 10.2147/COPD.S234942. - DOI - PMC - PubMed
    1. Akmatov M.K., Ermakova T., Holstiege J., Steffen A., von Stillfried D., Bätzing J. Comorbidity profile of patients with concurrent diagnoses of asthma and COPD in Germany. Sci. Rep. 2020;10:17945. doi: 10.1038/s41598-020-74966-1. - DOI - PMC - PubMed

MeSH terms

LinkOut - more resources